These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 33752428)

  • 21. Serum Homocysteine Level Is a Predictor of Relapse and Prognosis in Patients With First-Attack Neuromyelitis Optica Spectrum Disorders.
    Zhang J; Li Y; Zhou Y; Zhao Y; Xie H; Duan R; Yao Y; Gong Z; Teng J; Jia Y
    Front Neurol; 2021; 12():667651. PubMed ID: 34122309
    [No Abstract]   [Full Text] [Related]  

  • 22. Tocilizumab treatment in neuromyelitis optica spectrum disorders: Updated meta-analysis of efficacy and safety.
    Wang Y; Zhao M; Yao M; Yang Z; Li B; Yin L; Geng X
    Mult Scler Relat Disord; 2023 Dec; 80():105062. PubMed ID: 37866020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of pregnancy on neuromyelitis optica spectrum disorder and predictors of related attacks.
    Du Q; Shi Z; Chen H; Zhang Y; Qiu Y; Lang Y; Kong L; Zhou H
    Ann Clin Transl Neurol; 2022 Dec; 9(12):1918-1925. PubMed ID: 36314431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of Pain with Plasma C5a in Patients with Neuromyelitis Optica Spectrum Disorders During Remission.
    Tong Y; Liu J; Yang T; Wang J; Zhao T; Kang Y; Fan Y
    Neuropsychiatr Dis Treat; 2022; 18():1039-1046. PubMed ID: 35615424
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Exchange in Pediatric Neurology Patients: A Single-Center Experience.
    Aljezani MA; Althubaiti F; Alhamed L; Alharthi A; Alamoodi A; Bakheet Y; Badawi M; Hindawi S
    Cureus; 2024 Jan; 16(1):e52691. PubMed ID: 38384617
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Early clinical response and complications of therapeutic plasma exchange in central nervous system demyelinating diseases.
    Rashidi M; Naghavi S; Ramezani N; Ashtari F; Shaygannejad V; Hosseini SM; Adibi I
    J Cent Nerv Syst Dis; 2024; 16():11795735241262738. PubMed ID: 38903856
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunoadsorption and plasma exchange-Efficient treatment options for neurological autoimmune diseases.
    Boedecker SC; Luessi F; Engel S; Kraus D; Klimpke P; Holtz S; Meinek M; Marczynski P; Weinmann A; Weinmann-Menke J
    J Clin Apher; 2022 Feb; 37(1):70-81. PubMed ID: 34904748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent changes in the frequency of use of apheresis and biological drugs in the treatment of neuromyelitis optica spectrum disorders.
    Miyamoto K; Nakayama Y; Ito H
    Ther Apher Dial; 2023 Aug; 27(4):819-820. PubMed ID: 36826431
    [No Abstract]   [Full Text] [Related]  

  • 29. Facilities, selection, outcome measurement, and limitations of therapeutic plasma exchange for neuroimmunological disorders: The South East Asian survey study.
    Rattanathamsakul N; Siritho S; Viswanathan S; Hiew FL; Apiwattanakul M; Tan K; Thirugnanam UN; Yeo T; Quek AML; Estiasari R; Remli R; Aye SMM; Ohnmar O; Hoang NTT; Pasco PM
    J Clin Apher; 2023 Aug; 38(4):437-446. PubMed ID: 36896493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lymphoplasmapheresis versus plasma exchange in severe myasthenia gravis: a retrospective cohort study.
    Duan W; Jiang F; Cai H; Li B; Ouyang S; Yin W; Zeng Q; Yang H
    Front Neurol; 2023; 14():1212868. PubMed ID: 37441608
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Therapeutic Plasma Exchange in Children with Neuroimmunological Disorders: A Limited Unicentral Study.
    Nikkhah A; Nasehi MM; Momtazmanesh N; Etemad K; Hajatnia S
    Iran J Child Neurol; 2024; 18(2):31-41. PubMed ID: 38617399
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inpatient care of neuromyelitis optica spectrum disorder in Germany: Nationwide analysis from 2010 to 2021.
    Richter D; Bartig D; Tönges L; Kümpfel T; Schwake C; Gold R; Krogias C; Ayzenberg I
    Mult Scler J Exp Transl Clin; 2023; 9(3):20552173231184433. PubMed ID: 37435571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of IVIg and TPE efficacy in the treatment of neurological disorders: a systematic literature review.
    Pinto AA; De Seze J; Jacob A; Reddel S; Yudina A; Tan K
    Ther Adv Neurol Disord; 2023; 16():17562864231154306. PubMed ID: 37006460
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of plasma exchange or immunoadsorption for the treatment of option neuritis in demyelinating diseases: A systematic review and meta-analysis.
    Zhang J; Fan A; Wei L; Wei S; Xie L; Li M; Zhang W; Liu Q; Yang K
    Eur J Ophthalmol; 2022 Jul; 32(4):1857-1871. PubMed ID: 34918576
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic Plasma Exchange in Certain Immune-Mediated Neurological Disorders: Focus on a Novel Nanomembrane-Based Technology.
    Tonev DG; Momchilova AB
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830870
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consensus recommendation on the use of therapeutic plasma exchange for adult neurological diseases in Southeast Asia from the Southeast Asia therapeutic plasma exchange consortium.
    Hiew FL; Thit WM; Alexander M; Thirugnanam U; Siritho S; Tan K; Mya Aye SM; Ohnmar O; Estiasari R; Yassin N; Pasco PM; Keosodsay SS; Trong Nghia HT; Islam MB; Wong SK; Lee S; Chhabra A; Viswanathan S
    J Cent Nerv Syst Dis; 2021; 13():11795735211057314. PubMed ID: 35173510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent Advances in Neuromyelitis Optica Spectrum Disorder: Pathogenesis, Mechanisms and Potential Treatments.
    Du Y; Li K; Liu W; Song R; Luo M; He J; Xu X; Qu X
    Curr Pharm Des; 2022; 28(4):272-279. PubMed ID: 33781189
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Disability Outcomes in the N-MOmentum Trial of Inebilizumab in Neuromyelitis Optica Spectrum Disorder.
    Marignier R; Bennett JL; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk D; Fujihara K; Paul F; Cutter GR; Green AJ; Aktas O; Hartung HP; Lublin FD; Williams IM; Drappa J; She D; Cimbora D; Rees W; Smith M; Ratchford JN; Katz E; Cree BAC;
    Neurol Neuroimmunol Neuroinflamm; 2021 May; 8(3):. PubMed ID: 33771837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab and risk of COVID-19 infection and its severity in patients with MS and NMOSD.
    Esmaeili S; Abbasi MH; Abolmaali M; Mojtahed M; Alavi SNR; Soleimani S; Mokhtari M; Hatam J; Khotbehsara ST; Motamed MR; Joghataei MT; Mirzaasgari Z; Moghaddasi M
    BMC Neurol; 2021 May; 21(1):183. PubMed ID: 33933026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Serum Neurofilament Light and GFAP Are Associated With Disease Severity in Inflammatory Disorders With Aquaporin-4 or Myelin Oligodendrocyte Glycoprotein Antibodies.
    Chang X; Huang W; Wang L; ZhangBao J; Zhou L; Lu C; Wang M; Yu J; Li H; Li Y; Zhao C; Lu J; Quan C
    Front Immunol; 2021; 12():647618. PubMed ID: 33796113
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.